GSK bets $300 million on genetics as CEO plays down break-up talk

GlaxoSmithKline aims to turbo-charge its drug discovery engine with a big bet on genetics as its CEO on Wednesday played down the idea of hiving off consumer healthcare, which is a source of cash generation for such R&D investment.